Beyond risk-stratifying people, it is vital to have tools that accurately detect cancer. Historically, the lack of a clinically useful biomarker assay has challenged reliable detection. Recent studies conducted by Biological Dynamics show the effectiveness of next-generation biomarkers and advanced technology for early disease detection. Promising blood-based assays are now enabling higher sensitivity to early-stage disease using exosome-based biomarkers circulating in the blood. Combining AI identification and surveillance of high-risk individuals with these early detection tests has the potential to change our standard of care for those who need it most.

The future of surveillance and early detection
Traditional public health models offer general wellness guidelines to large, undifferentiated populations based on exposure and health history. Looking toward the future, health directives will become more tailored to individuals based on factors like family history, geographic location, diet, daily activities, and environmental exposures. The next wave of personalized medicine will also likely include genetic assessments as a routine part of medical and wellness care.
The use of AI to identify high-risk subjects, in conjunction with advanced diagnostic assays for ongoing surveillance, is bringing a promising new era to the fight against challenging diseases—each technology complementing the other and strengthening the chances of people receiving successful outcomes and a brighter future.

About the author: Dr. Paul R. Billings, MD, Ph.D., FACP, FACMGG, is the CEO and director of Biological Dynamics. He is devoted to studying and teaching medicine and genetics while accelerating the use of a broad range of novel genomic technologies in clinical settings. Over his decades in healthcare, he has established key business partnerships, driving the adoption of innovative discoveries and commercial success.

Back to HCB News

Business Affairs Homepage